Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

The combination of heart failure and chronic obstructive pulmonary disease presents many
therapeutic challenges. The cornerstones of therapy are beta-blockers and beta-agonists …

We review the cardiac safety of the drugs available at present for the maintenance treatment
of chronic obstructive pulmonary disease (COPD) in stable disease, focusing on inhaled …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …

Persons with Chronic Obstructive Pulmonary Disease (COPD) are at risk for developing
other smoking-related complications, including cardiac and vascular diseases. Information …

Background β-Adrenoceptor agonists (β-agonists) are commonly used to treat obstructive
lung diseases, and preliminary studies have suggested they are associated with an …

Background β-Blocker therapy has been shown to improve survival among patients with
ischaemic heart disease (IHD) and congestive heart failure (CHF) and is underused among …

Although large surveys have documented the favourable safety profile of β 2-adrenoceptor
agonists (β 2-agonists) and, above all, that of the long-acting agents, the presence in the …

Background: There is little data about the combined effects of COPD and obesity. We
compared dyspnea, health-related quality of life (HRQoL), exacerbations, and inhaled …

Chronic obstructive pulmonary disease (COPD) is independently associated with an
increased burden of cardiovascular disease. Besides coronary artery disease (CAD) and …